At a time of market uncertainty, what can an investor count on? Knee replacements, for one thing. Bruce Nudell, UBS senior research analyst, takes that as his cue in picking some promising stocks.
"We really love the orthopedic market right now," he told CNBC. "It’s got about, in the United States, about five points of unit growth; hospitals are making a lot of money on these procedures…So this should be a high single-digit market for the long term."
He's got a favorite among the orthopedics, too.
"We like Zimmer especially," he said. "We think it's an undervalued stock. We like Stryker in the orthopedic space as well; Abbott (Laboratories) we think is a terrific company, has terrific prospects right now."
And that's not all.
"Medtronic, I think, is going to have a really good year," he said, but added, "We question the longer-term topline there."
Zimmer's firm makes a market in the securities of Zimmer, Stryker, and Abbott Laboratories, and has received compensation within the last 12 months from Medtronic, which is an investment banking client of the firm.
-- Brooke Sopelsa contributed to this article.